BioSpace News Archive

John Houston brings more than 30 years of experience in drug discovery and development in pharma and biotech as Cybrexa prepares to transition to become a clinical-stage company

MLSC’s Milestone Achievement Program awards more than $1.9 million to 10 companies representing all major life sciences sectors

Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.

According to the U.S. Centers for Disease Control and Prevention, about 2 million people each year are infected with antibiotic-resistant bacteria and 23,000 people die as a result. A recent study by the UK government estimated that by 2050, as many as 10 million people could die worldwide from antibiotic-resistant infections.

Helping Health Professionals Combat The Vaccine Hesitancy Crisis

Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.

Starting from a chemical vendor in 2007, BOC Sciences has now become a well-established brand and is currently leading drug discovery and process R&D, in an attempt to help researchers engaged in this field to find a more efficient and cost-effective approach to early drug development.

Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.

Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.

Global Blood Therapeutics, Inc. announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time.